JSPR — Jasper Therapeutics Share Price
0.000.00%
Last trade - 00:00- $81.27m
- $9.63m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.32 | ||
| Price to Tang. Book | 1.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -117.9% | ||
| Return on Equity | -101.73% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 5.5 | 1.89 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 13th, 2019
- Public Since
- November 20th, 2019
- No. of Shareholders
- 8
- No. of Employees
- 64
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 15,022,122
- Address
- 2200 Bridge Pkwy Suite #102, REDWOOD CITY, 94065
- Web
- https://jaspertx.com/
- Phone
- +1 6505491400
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for JSPR
Jasper Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Jasper Therapeutics Inc Earnings Release
Similar to JSPR
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Jasper Therapeutics share price?
As of Today at 21:26 UTC, shares in Jasper Therapeutics are trading at $5.41. This share price information is delayed by 15 minutes.
How has the Jasper Therapeutics share price performed this year?
Shares in Jasper Therapeutics last closed at $5.41 and the price had moved by -77.44% over the past 365 days. In terms of relative price strength the Jasper Therapeutics share price has underperformed the S&P500 Index by -79.66% over the past year.
What are the analyst and broker recommendations for Jasper Therapeutics?
The overall consensus recommendation for Jasper Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Jasper Therapeutics dividend yield?
Jasper Therapeutics does not currently pay a dividend.
Does Jasper Therapeutics pay a dividend?
Jasper Therapeutics does not currently pay a dividend.
When does Jasper Therapeutics next pay dividends?
Jasper Therapeutics does not currently pay a dividend.
How do I buy Jasper Therapeutics shares?
To buy shares in Jasper Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Jasper Therapeutics?
As of the previous close price of $5.41, shares in Jasper Therapeutics had a market capitalisation of $81.27m.
Where are Jasper Therapeutics shares listed?
Here are the trading details for Jasper Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: JSPR
What kind of share is Jasper Therapeutics?
Based on an overall assessment of its quality, value and momentum Jasper Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Jasper Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Jasper Therapeutics is $50.63. That is 835.86% above the last closing price of $5.41.
Analysts covering Jasper Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$4.98 for the next financial year.
Find out moreWhat is the trend in the Jasper Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Jasper Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -74.45%.
As of the last closing price of $5.41, shares in Jasper Therapeutics were trading -62.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Jasper Therapeutics PE Ratio?
The Jasper Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Jasper Therapeutics?
We do not have data on Jasper Therapeutics' directors